Sponsor pipeline

Neurocrine Biosciences clinical trial pipeline

Get alerts when Neurocrine Biosciences's trials change

18 active trials 13 recruiting 12 Phase 3 5 disease areas 7 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-02

What changed in the last 30 days

2026-09-19
Primary completion pushed: 2027-01 → 2028-06
Enrollment increased: 50 → 100 participants
Trial sites reduced: 22 → 19 locations
Completion pushed: 2027-01 → 2028-06
NCT07105111 A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive… · Phase 4
2026-09-26
Trial sites expanded: 57 → 61 locations
NCT07114874 NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia · Phase 3
2026-09-26
Trial sites expanded: 20 → 25 locations
NCT07227818 Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia · Phase 3
2026-09-26
Trial sites expanded: 15 → 20 locations
NCT07105098 NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia · Phase 3

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-09-30 NCT07850739 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants… Phase 2 Not Yet Recruiting
2026-09-22 NCT07832383 Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD)… Phase 2 Not Yet Recruiting

Active trials by phase

Phase 2
5
Phase 3
12
Phase 4
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 4
NCT07105111 A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive… Schizophrenia Recruiting 2026-09-18
Phase 3
NCT07105098 NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia Schizophrenia Recruiting 2026-09-25
NCT07114874 NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia Schizophrenia Recruiting 2026-09-25
NCT07227818 Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia Schizophrenia Recruiting 2026-09-25
NCT06911112 NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an… Major Depressive Disorder Recruiting 2026-08-11
NCT06963021 NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an… Major Depressive Disorder Recruiting 2026-08-10
NCT06966401 Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive… Major Depressive Disorder Recruiting 2026-07-24
NCT07196501 A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in… Major Depressive Disorder Recruiting 2026-07-24
NCT06963034 NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia Schizophrenia Recruiting 2026-03-06
NCT06786624 Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in… Major Depressive Disorder Recruiting 2025-10-29
NCT06312189 Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With… Chorea, Huntington Enrolling by Invitation 2026-06-18
NCT04490915 Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal… Congenital Adrenal Hyperplasia Active, Not Recruiting 2026-05-11
NCT04806451 Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants… Congenital Adrenal Hyperplasia Active, Not Recruiting 2025-02-05
Phase 2
NCT07288320 An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With… Bipolar I Disorder Recruiting 2026-09-29
NCT07288333 Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia Schizophrenia Recruiting 2026-07-22
NCT07365462 Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive… Tardive Dyskinesia Recruiting 2026-06-23
NCT07850739 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants… Congenital Adrenal Hyperplasia Not Yet Recruiting 2026-09-30
NCT07832383 Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD)… Alzheimer's Disease Not Yet Recruiting 2026-09-22

Disease areas by active trials

Depression (6) · Schizophrenia (6) · Bipolar Disorder (2) · Alzheimer's Disease (1) · Huntington's Disease (1)

Get alerts when Neurocrine Biosciences's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free